HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Lowers Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Eton Pharmaceuticals (NASDAQ:ETON) but lowers the price target from $10 to $9.

July 03, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, Eton Pharmaceuticals maintains a 'Buy' rating from HC Wainwright & Co.
The lowered price target might indicate a perceived decrease in Eton's future performance. However, the maintained 'Buy' rating suggests that the analyst still sees potential in the company. This could lead to mixed market reactions, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100